ReviewPharmaceuticals (Basel, Switzerland)2021
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 64 citations in OpenAlex.
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Plant-Derived Modulators of Tumor Metabolism as Novel, Efficacious, and Low-Toxicity Therapeutic Agents for Cancer Treatment.Molecules (Basel, Switzerland) · 2026Review
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
- Quantitative Comparison of SPECT and PET Performance for Clinical Theranostic Applications.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- DFT calculation of AcScientific reports · 2026Article
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Unlocking drug development: the distinctive roles of PET and SPECT imaging from molecular kinetics to therapeutic response.Archives of pharmacal research · 2026Review
- Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.International journal of molecular sciences · 2025Review
- Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications.Pharmaceutics · 2025Review
- Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling.Scientific reports · 2025Article
- Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.Clinical Medicine Insights. Oncology · 2025Review
- An overview of the role of radionuclides in targeted cancer treatment: application of biomarkers for patient selection and developments to improve treatment efficacy.Frontiers in oncology · 2025Review
- Comparison of the dosimetry and cell survival effect ofEJNMMI physics · 2024Article
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Force Fields, Quantum-Mechanical- and Molecular-Dynamics-Based Descriptors of Radiometal-Chelator Complexes.Molecules (Basel, Switzerland) · 2024Article
- Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications.Molecules (Basel, Switzerland) · 2024Article
- Complexation of 3p-Heliyon · 2024Article
- RNA nanostructures for targeted drug delivery and imaging.RNA biology · 2024Review
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
Abstract
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.